EADO/WCM 2025 | Rethinking melanoma follow-up: patient education over routine imaging

Iris Zalaudek • 3 Apr 2025

EADO/WCM 2025

Melanoma Skin Cancer

Iris Zalaudek, MD, PhD, University of Trieste, Trieste, Italy, discusses the limitations of current melanoma follow-up protocols and the misconception that frequent imaging can significantly improve early metastatic detection. While stage pT1A melanoma has a 98% survival rate over 10 years, a small subset of patients may still progress. Prof. Zalaudek emphasizes that follow-up schedules are arbitrary, as melanoma progresses unpredictably. Importantly, over 50% of metastases are self-detected, highlighting the need to educate patients on recognizing warning signs and ensuring rapid access to care. This interview took place at the 11th World Congress of Melanoma and 21st EADO Congress in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.